Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

Objetivo

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, with ~32,000 new cases annually in Europe and a disease burden that has more than doubled over the past three decades. Despite significant advances with BTK and BCL-2 inhibitors, CLL remains incurable. Acquired resistance driven by the immunosuppressive tumour microenvironment (TME) leads to inevitable relapse in most patients. This challenge is shared across B-cell neoplasias, including non-Hodgkin lymphoma, diffuse large B-cell lymphoma and acute lymphoblastic leukemia, which together affect over 100,000 patients annually in Europe and are treated with overlapping immunotherapeutic strategies. Supramolecular attack particles (SMAPs) are stable, acellular glycoprotein nanostructures released by cytotoxic T and NK cells that encapsulate toxic molecules and induce cell death autonomously. Lacking a lipid membrane, SMAPs evade TME suppression, resist immune rejection, and have a long shelf life, properties that position them as promising off-the-shelf cytotoxic agents. However, as isolated nanoparticles, SMAPs lack tumour-targeting capacity, causing non-specific toxicity and preventing clinical translation. We have engineered the SMAP glycoprotein shell to confer tumour specificity. Preliminary data confirm that the chimeric SMAPs have full cytotoxic potency and the ability to selectively kill CLL cells. This ERC PoC project will translate these findings through three objectives: (1) optimising the engineered SMAPs for stable production and yield; (2) engineering a scalable cytotoxic cell line as a SMAP bioreactor; and (3) establishing a purification pipeline for preclinical testing. Success will lay the foundation for a cell free,off-the-shelf immunotherapy for CLL and the broader B-cell neoplasias.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-POC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

UNIVERSITA DEGLI STUDI DI SIENA
Aportación neta de la UEn
€ 150 000,00
Dirección
VIA BANCHI DI SOTTO 55
53100 Siena
Italia
Región
Centro (IT) Toscana Siena
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Beneficiarios (1)

Socios (1)